AbbVie Inc. Q3-2025
Health Care · Pharmaceuticals
Operator Signal: NEUTRAL
This filing is a pre-earnings guidance update, not a full earnings call. AbbVie disclosed $2.7B in acquired IPR&D and milestones expense hitting Q3, which crushed adjusted EPS guidance down to $1.74-$1.78 for the quarter. Full-year adjusted EPS guided to $10.38-$10.58.
If you're building in pharma/biotech services, AbbVie's $2.7B IPR&D spend signals aggressive pipeline acquisition — expect continued deal flow and integration demand in the pharma services ecosystem.
AI Intelligence
○ HYPENo AI mentions in this 8-K filing. AbbVie's AI posture cannot be assessed from this document.
What They Actually Said
“Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2025 are expected to include acquired IPR&D and milestones expense of $2.7 billion on a pre-tax basis, representing an unfavorable impact of $1.50 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share.”
— AbbVie Inc., 8-K Filingm-and-aguidance
“AbbVie's full-year 2025 adjusted diluted earnings per share guidance range, including the impact of third quarter 2025 acquired IPR&D and milestones expense, is $10.38 - $10.58.”
— AbbVie Inc., 8-K Filingguidance
“AbbVie's third quarter 2025 adjusted diluted earnings per share guidance range, including the impact of third quarter 2025 acquired IPR&D and milestones expense, is $1.74 - $1.78.”
— AbbVie Inc., 8-K Filingguidance